Opens in a new tab or window The FDA approved sirolimus 0.2% gel (Hyftor) as the first topical treatment for facial angiofibroma associated with tuberous sclerosis complex (TSC), Nobelpharma ...

Credit: FDA. The approval was based on data from a phase 3 trial that assessed Hyftor in 62 patients with facial angiofibroma associated with TSC. The Food and Drug Administration (FDA) has ...

Nobelpharma America has become the first company to win FDA approval for a topical treatment for facial angiofibroma associated with tuberous sclerosis complex (TSC). The approval covers a topical ...

Hyftor 0.2% topical gel is supplied in 10 gram tubes containing 2mg of sirolimus per gram; it is available through a limited network of specialty pharmacies. Hyftor ™ (sirolimus topical gel) is ...

In April 2022, Nobelpharma became the first U.S. pharma to get FDA approval for a topical treatment for facial angiofibroma. Prior to the approval, traditional treatment options included ...

NICE is unable to make a recommendation on sirolimus (Hyftor) for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over. This is because Plusultra pharma did not ...

Facial angiofibromas associated with TSC are facial ... nose, and chin. Without treatment, they may cause significant disfiguration, bleeding, pruritus, and erythema. HYFTOR is a prescription ...

Juvenile nasopharyngeal angiofibroma (JNA) is a rare ... During your visit, they will explain your treatment options. They will answer any questions you might have. They may schedule imaging tests to ...

Facial angiofibromas associated with TSC are facial ... nose, and chin. Without treatment, they may cause significant disfiguration, bleeding, pruritus, and erythema. About Nobelpharma America ...